Every round on record, with the sources behind each and the investors on them.
An AI platform that designs drug combinations for cancer
bigpicturebio.comLondon, UKHealthtech
| Round | Amount | Announced | Lead | Verified | Status | Sources |
|---|---|---|---|---|---|---|
| Pre-seed pre-seed | $2.0M £1.5 million | 2026-09-17 | Kadmos Capital, Exceptional Ventures | 4 | [ PUBLISHED ] | 4 |
[ VERIFIED · CORRECTED ]0.86 reconciled across 4 sources by gpt-5.6-luna
[ BUILT WITH ]·[ SEARCH ]found by Firecrawl search: "pre-seed round" led by announces·[ SCRAPE ]4 pages read: european-biotechnology.com, drugtargetreview.com, news-medical.net·[ JSON ]round extracted with a schema, grounded to one sentence·[ VERIFY ]correctedread back across 4 sources by gpt-5.6-luna·[ BRANDING ]logo and colour from the homepage·[ AGENT ]dossier built by the Firecrawl agent | ||||||
Big Picture Bio builds a generative world model that predicts drug combinations for pharma, biotech and investors working on cancer and other complex diseases.
| Round | Amount | Announced | Lead |
|---|---|---|---|
| pre-seed | £1.5 million (~$2 million USD) | 2026-09-17 | Kadmos Capital, Exceptional Ventures |
Big Picture Bio says more than 900 billion drug combinations are possible, making it impractical for laboratories to test their way to the right cancer therapies, while its model is intended to identify combinations and sequences that are more likely to work in patients. The £2.2 million in combined equity and non-dilutive funding is moving its first computationally designed combinations into wet-lab validation, a key test of whether its predictions can produce synergistic therapies.
Exceptional Ventures
Kadmos Capital
Gloucester Ventures